{\rtf1\ansi\ansicpg1252\deff0\deflang1033{\fonttbl{\f0\fswiss\fprq2\fcharset0 Arial;}{\f1\froman\fprq2\fcharset0 Times New Roman;}{\f2\fswiss\fprq2\fcharset0 Arial Black;}}{\colortbl;\red0\green0\blue0;\red255\green0\blue0;\red0\green128\blue0;\red0\green0\blue255;}\viewkind4\uc1\pard\sa200\sl276\slmult1\f0\fs40\b\qc Tables, Figures, and Listings\par\fs32 Mock Shells for Clinical Study Report\par\fs24\par\pard\fs24\b Study Title: \b0 A Phase III Study of Drug X in Patients with Neurological Disorders\par\b Protocol Number: \b0 DEF-765\par\b Sponsor: \b0 BioTech Laboratories\par\b Date: \b0 06 January 2026\par\par\page\fs32\b\qc Table of Contents\par\pard\fs24\par\b 1.0 TABLES\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_1_1"}}{\fldrslt{\ul\cf4 Table 14.1.1: Demographics and Baseline Characteristics\tab Page 4}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_1_2"}}{\fldrslt{\ul\cf4 Table 14.1.2: Medical History\tab Page 5}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_1_3"}}{\fldrslt{\ul\cf4 Table 14.1.3: Demographics by Subgroup (Age, Sex, Race)\tab Page 6}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_1_4"}}{\fldrslt{\ul\cf4 Table 14.1.4: Prior and Concomitant Medications\tab Page 7}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_2_1"}}{\fldrslt{\ul\cf4 Table 14.2.1: Primary Efficacy Analysis - Change from Baseline at Week 12\tab Page 8}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_2_2"}}{\fldrslt{\ul\cf4 Table 14.2.2: Secondary Efficacy Analysis - Key Secondary Endpoints\tab Page 9}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_2_3"}}{\fldrslt{\ul\cf4 Table 14.2.3: Time-to-Event Analysis - Kaplan-Meier Estimates\tab Page 10}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_2_4"}}{\fldrslt{\ul\cf4 Table 14.2.4: Binary Endpoint Analysis\tab Page 11}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_2_5"}}{\fldrslt{\ul\cf4 Table 14.2.5: Subgroup Analysis of Primary Endpoint\tab Page 12}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_3_1"}}{\fldrslt{\ul\cf4 Table 14.3.1: Treatment-Emergent Adverse Events\tab Page 13}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_3_2"}}{\fldrslt{\ul\cf4 Table 14.3.2: Laboratory Test Results - Hematology\tab Page 14}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_3_3"}}{\fldrslt{\ul\cf4 Table 14.3.3: Laboratory Test Results - Chemistry\tab Page 15}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_3_4"}}{\fldrslt{\ul\cf4 Table 14.3.4: Vital Signs Summary\tab Page 16}}}\par{\field{\*\fldinst{HYPERLINK \\l "tbl_14_3_5"}}{\fldrslt{\ul\cf4 Table 14.3.5: Shift Table for Laboratory Parameters\tab Page 17}}}\par\par\b 2.0 FIGURES\par{\field{\*\fldinst{HYPERLINK \\l "fig_14_2_1"}}{\fldrslt{\ul\cf4 Figure 14.2.1: Primary Endpoint Over Time (Line Plot)\tab Page 18}}}\par{\field{\*\fldinst{HYPERLINK \\l "fig_14_2_2"}}{\fldrslt{\ul\cf4 Figure 14.2.2: Subgroup Analysis of Primary Endpoint (Forest Plot)\tab Page 19}}}\par{\field{\*\fldinst{HYPERLINK \\l "fig_14_2_3"}}{\fldrslt{\ul\cf4 Figure 14.2.3: Kaplan-Meier Plot of Time to Event\tab Page 20}}}\par{\field{\*\fldinst{HYPERLINK \\l "fig_14_2_4"}}{\fldrslt{\ul\cf4 Figure 14.2.4: Box Plots of Primary Endpoint by Visit\tab Page 21}}}\par{\field{\*\fldinst{HYPERLINK \\l "fig_14_3_1"}}{\fldrslt{\ul\cf4 Figure 14.3.1: Adverse Events by System Organ Class (Bar Chart)\tab Page 22}}}\par{\field{\*\fldinst{HYPERLINK \\l "fig_14_3_2"}}{\fldrslt{\ul\cf4 Figure 14.3.2: Correlation of Primary Endpoint with Key Biomarker (Scatter Plot)\tab Page 23}}}\par\par\b 3.0 LISTINGS\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_1"}}{\fldrslt{\ul\cf4 Listing 16.2.1: Patient Disposition\tab Page 24}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_2"}}{\fldrslt{\ul\cf4 Listing 16.2.2: Protocol Deviations\tab Page 25}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_3"}}{\fldrslt{\ul\cf4 Listing 16.2.3: Patients Excluded from Analysis\tab Page 26}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_4"}}{\fldrslt{\ul\cf4 Listing 16.2.4: Demographic Data\tab Page 27}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_5"}}{\fldrslt{\ul\cf4 Listing 16.2.5: Concomitant Medications\tab Page 28}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_6"}}{\fldrslt{\ul\cf4 Listing 16.2.6: Individual Efficacy Response Data\tab Page 29}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_7"}}{\fldrslt{\ul\cf4 Listing 16.2.7: Adverse Event Listings (Safety Population)\tab Page 30}}}\par{\field{\*\fldinst{HYPERLINK \\l "list_16_2_8"}}{\fldrslt{\ul\cf4 Listing 16.2.8: Individual Laboratory Measurements\tab Page 31}}}\par\par\page\fs32\b\qc 1.0 TABLES\par\pard\fs24\par{\*\bkmkstart tbl_14_1_1}\b Table 14.1.1: Demographics and Baseline Characteristics\b0\par{\*\bkmkend tbl_14_1_1}\par\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500\b Characteristic\cell Statistic\cell Treatment A\line(N=XX)\cell Treatment B\line(N=XX)\cell Total\line(N=XX)\b0\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 Age (years)\cell n\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 \cell Mean (SD)\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 \cell Median\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 \cell Min, Max\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 Sex, n (%)\cell\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 Male\cell n (%)\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx2000\cellx3000\cellx4500\cellx6000\cellx7500 Female\cell n (%)\cell\cell\cell\cell\row\pard\par\i SD = standard deviation; BMI = body mass index\parNote: Percentages are based on the number of patients in the analysis population within each treatment group.\i0\par\page{\*\bkmkstart tbl_14_1_3}\b Table 14.1.3: Demographics by Subgroup (Age, Sex, Race)\b0\par{\*\bkmkend tbl_14_1_3}\par\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500\b Subgroup\cell Statistic\cell Treatment A\line(N=XX)\cell Treatment B\line(N=XX)\b0\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Age < 65 years\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Age ≥ 65 years\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Male\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Female\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 White\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Black or African American\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Asian\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx2500\cellx3500\cellx5000\cellx6500 Other\cell n (%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\pard\par\i Note: Percentages are calculated based on the number of patients in each treatment group.\i0\par\page{\*\bkmkstart tbl_14_1_4}\b Table 14.1.4: Prior and Concomitant Medications\b0\par{\*\bkmkend tbl_14_1_4}\par\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000\b ATC Level 2 Classification\line Preferred Name\cell Treatment A\line(N=XX)\line n (%)\cell Treatment B\line(N=XX)\line n (%)\cell Total\line(N=XX)\line n (%)\b0\cell\row\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000 Analgesics\cell XX (XX.X%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000    Acetaminophen\cell XX (XX.X%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000    Ibuprofen\cell XX (XX.X%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000 Antihypertensives\cell XX (XX.X%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000    Lisinopril\cell XX (XX.X%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\trowd\trgaph108\trleft-108\cellx3500\cellx5000\cellx6500\cellx8000    Amlodipine\cell XX (XX.X%)\cell XX (XX.X%)\cell XX (XX.X%)\cell\row\pard\par\i ATC = Anatomical Therapeutic Chemical Classification System.\parNote: Medications were coded using WHO Drug Dictionary. A patient with multiple medications within a category is counted only once in that category.\i0\par\page{\*\bkmkstart tbl_14_1_2}\b Table 14.1.2: Medical History\b0\par{\*\bkmkend tbl_14_1_2}\par\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500\b Medical History\line System Organ Class\line   Preferred Term\cell Treatment A\line(N=XX)\line n (%)\cell Treatment B\line(N=XX)\line n (%)\cell Total\line(N=XX)\line n (%)\b0\cell\row\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500 Blood and lymphatic system disorders\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500    Anemia\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500    Leukopenia\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500 Cardiac disorders\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500    Atrial fibrillation\cell\cell\cell\cell\row\trowd\trgaph108\trleft-108\cellx3000\cellx4500\cellx6000\cellx7500    Hypertension\cell\cell\cell\cell\row\pard\par\i Note: Medical history was coded using MedDRA version XX.X. A patient with multiple events within a category is counted only once in that category.\parPercentages are calculated based on the number of patients in the safety population.\i0\par\page{\*\bkmkstart tbl_14_2_1}\b Table 14.2.1: Primary Efficacy Analysis - Change from Baseline at Week 12 (Full Analysis Set Population)\b0\par{\*\bkmkend tbl_14_2_1}\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment A\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment B\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Difference\line(95% CI)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  p-value\b0\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Primary Endpoint\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  n\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Baseline, Mean (SD)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Week 12, Mean (SD)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  LS Mean (SE)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx6500\cellx7500\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Change from Baseline,\line LS Mean (SE)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\pard\par\i CI = confidence interval; SD = standard deviation; SE = standard error; LS = least squares\parNote: The primary analysis was based on a mixed model for repeated measures (MMRM) with treatment, visit, and treatment-by-visit interaction as fixed effects, and baseline value as a covariate.\i0\par\page{\*\bkmkstart tbl_14_2_2}\b Table 14.2.2: Secondary Efficacy Analysis - Key Secondary Endpoints (Full Analysis Set Population)\b0\par{\*\bkmkend tbl_14_2_2}\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Endpoint\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment A\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment B\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  LS Mean Difference\line(95% CI)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  p-value\b0\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Secondary Endpoint 1\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  n\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  LS Mean (SE)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  ANCOVA p-value\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\pard\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Secondary Endpoint 2\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  n\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  LS Mean (SE)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X (X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2500\cellx3800\cellx5100\cellx6400\cellx7700\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  ANCOVA p-value\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\pard\par\i CI = confidence interval; SE = standard error; LS = least squares\parNote: The analysis was based on an Analysis of Covariance (ANCOVA) model with treatment as fixed effect and baseline value as a covariate.\i0\par\page{\*\bkmkstart tbl_14_2_3}\b Table 14.2.3: Time-to-Event Analysis - Kaplan-Meier Estimates (Full Analysis Set Population)\b0\par{\*\bkmkend tbl_14_2_3}\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Parameter\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment A\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment B\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Hazard Ratio\line(95% CI)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Log-rank\line p-value\b0\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Number of events, n (%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX (XX.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX (XX.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Censored, n (%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX (XX.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX (XX.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Median time to event\line(95% CI), months\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X\line(XX.X, XX.X)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X\line(XX.X, XX.X)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  6-month event-free rate\line(95% CI), %\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X\line(XX.X, XX.X)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X\line(XX.X, XX.X)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  12-month event-free rate\line(95% CI), %\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X\line(XX.X, XX.X)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX.X\line(XX.X, XX.X)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8500\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Hazard ratio (95% CI)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XX (0.XX, 0.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\pard\par\i CI = confidence interval\parNote: Hazard ratio and 95% CI were calculated using a Cox proportional hazards model with treatment as a factor. p-value was calculated using a stratified log-rank test.\i0\par\page{\*\bkmkstart tbl_14_2_4}\b Table 14.2.4: Binary Endpoint Analysis (Full Analysis Set Population)\b0\par{\*\bkmkend tbl_14_2_4}\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Response Variable\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment A\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment B\line(N=XX)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Odds Ratio\line(95% CI)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  p-value\b0\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Clinical Response\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  n\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Responders, n (%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX (XX.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX (XX.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Odds Ratio (95% CI)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\pard\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Complete Response\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  n\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Responders, n (%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X (X.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X (X.X%)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3500\cellx5000\cellx7000\cellx8000\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Odds Ratio (95% CI)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  0.XXX\cell\row\pard\par\i CI = confidence interval\parNote: Odds ratios, 95% CIs, and p-values were calculated using logistic regression with treatment as the only factor. p-values are based on a two-sided binomial test for difference in proportions.\i0\par\page{\*\bkmkstart tbl_14_2_5}\b Table 14.2.5: Subgroup Analysis of Primary Endpoint\b0\par{\*\bkmkend tbl_14_2_5}\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Subgroup\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 Treatment A\line(n/N)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 Treatment B\line(n/N)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 Treatment Effect\line(95% CI)\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 p-value for\line interaction\b0\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 Overall\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Age\b0\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 0.XXX\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 < 65 years\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 ≥ 65 years\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Sex\b0\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 0.XXX\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 Male\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx2000\cellx3000\cellx4000\cellx5000\cellx7000\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 Female\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 XX/XX\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 X.XX (X.XX, X.XX)\cell\clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \cell\row\pard\par\i CI = confidence interval\parNote: Treatment effect is expressed as the difference in LS means for continuous endpoints or odds ratio for binary endpoints.\i0\par\page\fs32\b\qc 2.0 FIGURES\par\pard\fs24\par{\*\bkmkstart fig_14_2_1}{\*\bkmkstart figure_14_2_1}\b Figure 14.2.1: Primary Endpoint Over Time (Line Plot)\b0\par{\*\bkmkend figure_14_2_1}\par\pard\qc\par Line Plot: Primary Endpoint Score Over Time \par\par\qc\b{\pard\qc\brdrbox\brdrdash\brdrw15\par\par Line Graph: Shows trend over time with error bars \par[Treatment A shows improvement compared to Treatment B] \par\par}\b0\pard\par\i Note: Error bars represent standard error of the mean. Primary analysis population (N=XXX).\i0\par{\*\bkmkend fig_14_2_1}\page{\*\bkmkstart fig_14_2_2}{\*\bkmkstart figure_14_2_2}\b Figure 14.2.2: Subgroup Analysis of Primary Endpoint (Forest Plot)\b0\par{\*\bkmkend figure_14_2_2}\par\pard\qc\par Forest Plot: Treatment Effect by Subgroup \par\par\qc\b{\pard\qc\brdrbox\brdrdash\brdrw15\par\par Forest Plot: Hazard ratios with confidence intervals \par[Multiple subgroups showing treatment effect] \par\par}\b0\pard\par\i Note: Horizontal lines represent 95% confidence intervals. Size of the square is proportional to the number of subjects.\i0\par{\*\bkmkend fig_14_2_2}\page{\*\bkmkstart fig_14_2_3}{\*\bkmkstart figure_14_2_3}\b Figure 14.2.3: Kaplan-Meier Plot of Time to Event\b0\par{\*\bkmkend figure_14_2_3}\par\pard\qc\par Kaplan-Meier Plot: Time to Event \par\par\qc\b{\pard\qc\brdrbox\brdrdash\brdrw15\par\par Kaplan-Meier Curve: Survival probability over time \par[Treatment A shows improved survival vs Treatment B] \par\par}\b0\pard\par\i Note: Vertical tick marks indicate censored observations. P-value is from log-rank test.\i0\par{\*\bkmkend fig_14_2_3}\page{\*\bkmkstart fig_14_2_4}{\*\bkmkstart figure_14_2_4}\b Figure 14.2.4: Box Plots of Primary Endpoint by Visit\b0\par{\*\bkmkend figure_14_2_4}\par\pard\qc\par Box Plot: Primary Endpoint by Visit \par\par\qc\b{\pard\qc\brdrbox\brdrdash\brdrw15\par\par Box Plot: Distribution of values by treatment group \par[Shows median, quartiles, and outliers] \par\par}\b0\pard\par\i Note: Boxes indicate interquartile range, horizontal line represents median, whiskers extend to min/max values excluding outliers.\i0\par{\*\bkmkend fig_14_2_4}\page{\*\bkmkstart fig_14_3_1}{\*\bkmkstart figure_14_3_1}\b Figure 14.3.1: Adverse Events by System Organ Class (Bar Chart)\b0\par{\*\bkmkend figure_14_3_1}\par\pard\qc\par Bar Chart: Adverse Events by System Organ Class \par\par\qc\b{\pard\qc\brdrbox\brdrdash\brdrw15\par\par Bar Chart: Frequency comparison between groups \par[Compares frequencies across multiple categories] \par\par}\b0\pard\par\i Note: GI=Gastrointestinal, CV=Cardiovascular, RS=Respiratory, NS=Nervous System, ME=Metabolism, IN=Infections, SK=Skin disorders.\i0\par{\*\bkmkend fig_14_3_1}\page{\*\bkmkstart fig_14_3_2}{\*\bkmkstart figure_14_3_2}\b Figure 14.3.2: Correlation of Primary Endpoint with Key Biomarker (Scatter Plot)\b0\par{\*\bkmkend figure_14_3_2}\par\pard\qc\par Scatter Plot: Correlation of Primary Endpoint with Biomarker \par\par\qc\b{\pard\qc\brdrbox\brdrdash\brdrw15\par\par Scatter Plot: Correlation between variables \par[Shows positive correlation with regression line] \par\par}\b0\pard\par\i Note: Correlation coefficient (r) calculated using Pearson's method. Line represents best linear fit.\i0\par{\*\bkmkend fig_14_3_2}\page\fs32\b\qc 3.0 LISTINGS\par\pard\fs24\par{\*\bkmkstart list_16_2_1}\b Listing 16.2.1: Patient Disposition\b0\par{\*\bkmkend list_16_2_1}\par\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx5500\cellx7500\b Study ID\cell Treatment Group\cell Patient ID\cell Randomized\cell Completed Study\cell Reason for Discontinuation\b0\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx5500\cellx7500 STUDY001\cell A\cell SUBJ-1001\cell Yes\cell No\cell Lost to Follow-up\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx5500\cellx7500 STUDY001\cell B\cell SUBJ-1002\cell Yes\cell Yes\cell \cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx5500\cellx7500 STUDY001\cell A\cell SUBJ-1003\cell Yes\cell Yes\cell \cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx5500\cellx7500 STUDY001\cell B\cell SUBJ-1004\cell Yes\cell No\cell Withdrawal by Subject\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx5500\cellx7500 STUDY001\cell A\cell SUBJ-1005\cell Yes\cell Yes\cell \cell\row\pard\par\i Note: This listing provides patient disposition information for all randomized patients.\i0\par\page{\*\bkmkstart list_16_2_2}\b Listing 16.2.2: Protocol Deviations\b0\par{\*\bkmkend list_16_2_2}\par\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx8000\b Study ID\cell Treatment Group\cell Patient ID\cell Date\cell Description\b0\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx8000 STUDY001\cell A\cell SUBJ-1001\cell 2023-03-25\cell Visit conducted outside window\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx8000 STUDY001\cell B\cell SUBJ-1003\cell 2023-09-02\cell Missed assessment\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx4500\cellx8000 STUDY001\cell B\cell SUBJ-1005\cell 2023-08-18\cell Visit conducted outside window\cell\row\pard\par\i Note: This listing provides all protocol deviations recorded during the study.\i0\par\page{\*\bkmkstart list_16_2_3}\b Listing 16.2.3: Patients Excluded from Analysis\b0\par{\*\bkmkend list_16_2_3}\par\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx5000\cellx8000\b Study ID\cell Treatment Group\cell Patient ID\cell Analysis Population\cell Reason for Exclusion\b0\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx5000\cellx8000 STUDY001\cell A\cell SUBJ-1020\cell Per Protocol\cell Took prohibited medication\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx5000\cellx8000 STUDY001\cell B\cell SUBJ-1021\cell Per Protocol\cell Less than 80% treatment compliance\cell\row\trowd\trgaph108\trleft-108\cellx1000\cellx2000\cellx3500\cellx5000\cellx8000 STUDY001\cell A\cell SUBJ-1022\cell Per Protocol\cell Took prohibited medication\cell\row\pard\par\i Note: This listing provides all patients excluded from the Per Protocol analysis population.\i0\par\page{\*\bkmkstart list_16_2_4}\b Listing 16.2.4: Demographic Data\b0\par{\*\bkmkend list_16_2_4}\par\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\cellx7200\cellx8000\cellx8800\b Study ID\cell Center\cell Patient ID\cell Treatment\cell Age (years)\cell Sex\cell Race\cell Ethnicity\cell Height (cm)\cell Weight (kg)\cell BMI (kg/m²)\b0\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\cellx7200\cellx8000\cellx8800 STUDY001\cell 001\cell SUBJ-1001\cell A\cell 70\cell Male\cell White\cell Hispanic\cell 185\cell 86\cell 25.1\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\cellx7200\cellx8000\cellx8800 STUDY001\cell 001\cell SUBJ-1002\cell B\cell 47\cell Female\cell Black\cell Not Hispanic\cell 161\cell 57\cell 22.0\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\cellx7200\cellx8000\cellx8800 STUDY001\cell 001\cell SUBJ-1003\cell A\cell 44\cell Male\cell Asian\cell Not Hispanic\cell 170\cell 88\cell 30.4\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\cellx7200\cellx8000\cellx8800 STUDY001\cell 001\cell SUBJ-1004\cell B\cell 49\cell Female\cell White\cell Not Hispanic\cell 190\cell 64\cell 17.7\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\cellx7200\cellx8000\cellx8800 STUDY001\cell 001\cell SUBJ-1005\cell A\cell 62\cell Male\cell Black\cell Hispanic\cell 161\cell 93\cell 35.9\cell\row\pard\par\i BMI = body mass index\parNote: This listing provides demographic information for all randomized patients.\i0\par\page{\*\bkmkstart list_16_2_5}\b Listing 16.2.5: Concomitant Medications\b0\par{\*\bkmkend list_16_2_5}\par\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600\b Study ID\cell Treatment Group\cell Patient ID\cell Medication\cell Indication\cell Start Date\cell End Date\cell Dose/Frequency\b0\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Acetaminophen\cell Headache\cell 2023-02-27\cell Ongoing\cell 1000 mg BID\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Ibuprofen\cell Arthritis\cell 2023-01-11\cell 2023-04-08\cell 25 mg QD\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell B\cell SUBJ-1003\cell Lisinopril\cell Hypertension\cell 2023-02-14\cell 2023-11-26\cell 10 mg BID\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell A\cell SUBJ-1004\cell Metformin\cell Diabetes\cell 2023-05-28\cell Ongoing\cell 10 mg BID\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell B\cell SUBJ-1005\cell Atorvastatin\cell Hypercholesterolemia\cell 2023-06-26\cell 2023-08-01\cell 10 mg BID\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell B\cell SUBJ-1001\cell Levothyroxine\cell Hypothyroidism\cell 2023-03-09\cell 2023-10-28\cell 1000 mg BID\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3600\cellx4800\cellx6000\cellx7200\cellx8600 STUDY001\cell A\cell SUBJ-1002\cell Amlodipine\cell Hypertension\cell 2023-05-24\cell Ongoing\cell 10 mg BID\cell\row\pard\par\i QD = once daily; BID = twice daily\parNote: This listing provides all concomitant medications taken during the study period.\i0\par\page{\*\bkmkstart list_16_2_6}\b Listing 16.2.6: Individual Efficacy Response Data\b0\par{\*\bkmkend list_16_2_6}\par\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400\b Study ID\cell Treatment Group\cell Patient ID\cell Visit\cell Visit Day\cell Actual Date\cell Score\cell Change\b0\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1001\cell Baseline\cell 1\cell 2023-10-24\cell 73\cell N/A\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 29\cell 2023-05-26\cell 69\cell -4\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1001\cell Week 8\cell 57\cell 2023-08-16\cell 63\cell -10\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 85\cell 2023-09-03\cell 54\cell -19\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1001\cell Week 16\cell 113\cell 2023-12-16\cell 47\cell -26\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1002\cell Baseline\cell 1\cell 2023-10-24\cell 73\cell N/A\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 29\cell 2023-05-12\cell 72\cell -1\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1002\cell Week 8\cell 57\cell 2023-12-10\cell 65\cell -8\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 85\cell 2023-11-18\cell 66\cell -7\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1002\cell Week 16\cell 113\cell 2023-10-09\cell 59\cell -14\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1003\cell Baseline\cell 1\cell 2023-06-06\cell 78\cell N/A\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 29\cell 2023-08-22\cell 72\cell -6\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1003\cell Week 8\cell 57\cell 2023-04-23\cell 65\cell -13\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 85\cell 2023-11-14\cell 62\cell -16\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell A\cell SUBJ-1003\cell Week 16\cell 113\cell 2023-03-21\cell 52\cell -26\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1004\cell Baseline\cell 1\cell 2023-07-27\cell 65\cell N/A\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1004\cell Week 4\cell 29\cell 2023-04-05\cell 62\cell -3\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1004\cell Week 8\cell 57\cell 2023-07-17\cell 61\cell -4\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1004\cell Week 12\cell 85\cell 2023-02-19\cell 57\cell -8\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6400 STUDY001\cell B\cell SUBJ-1004\cell Week 16\cell 113\cell 2023-07-26\cell 53\cell -12\cell\row\pard\par\i Note: Higher scores indicate worse disease status. Change is from baseline.\i0\par\page{\*\bkmkstart list_16_2_7}\b Listing 16.2.7: Adverse Event Listings (Safety Population)\b0\par{\*\bkmkend list_16_2_7}\par\trowd\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx700\cellx1400\cellx2100\cellx2800\cellx3500\cellx4200\cellx4900\cellx5600\cellx6300\cellx7000\cellx7700\cellx8400\cellx9100\cellx9800\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10 \b Study ID\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Center\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Patient ID\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Treatment\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  SOC\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Preferred Term\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Start Date\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  End Date\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Ongoing\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Severity\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Serious\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Related\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Action\cell\clbrdrt\brdrs\brdrw10 \clbrdrl\brdrs\brdrw10 \clbrdrb\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Outcome\b0\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx700\cellx1400\cellx2100\cellx2800\cellx3500\cellx4200\cellx4900\cellx5600\cellx6300\cellx7000\cellx7700\cellx8400\cellx9100\cellx9800\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  STUDY001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  SUBJ-1001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  A\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  GI disorders\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Nausea\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  15JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  28JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Mild\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Yes\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  None\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Recovered\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx700\cellx1400\cellx2100\cellx2800\cellx3500\cellx4200\cellx4900\cellx5600\cellx6300\cellx7000\cellx7700\cellx8400\cellx9100\cellx9800\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  STUDY001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  SUBJ-1002\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  B\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Nervous system\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Headache\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  15JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  28JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Moderate\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Yes\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Dose reduced\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Recovered\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx700\cellx1400\cellx2100\cellx2800\cellx3500\cellx4200\cellx4900\cellx5600\cellx6300\cellx7000\cellx7700\cellx8400\cellx9100\cellx9800\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  STUDY001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  SUBJ-1003\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  A\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Nervous system\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Headache\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  15JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  \cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Yes\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Severe\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  None\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Ongoing\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx700\cellx1400\cellx2100\cellx2800\cellx3500\cellx4200\cellx4900\cellx5600\cellx6300\cellx7000\cellx7700\cellx8400\cellx9100\cellx9800\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  STUDY001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  SUBJ-1004\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  B\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  GI disorders\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Nausea\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  15JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  28JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Mild\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Yes\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Dose reduced\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Recovered\cell\row\trowd\trbrdrl\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trgaph108\trleft-108\cellx700\cellx1400\cellx2100\cellx2800\cellx3500\cellx4200\cellx4900\cellx5600\cellx6300\cellx7000\cellx7700\cellx8400\cellx9100\cellx9800\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  STUDY001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  001\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  SUBJ-1005\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  A\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Nervous system\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Headache\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  15JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  28JAN2025\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Moderate\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Yes\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  No\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  None\cell\clbrdrl\brdrs\brdrw10 \clbrdrr\brdrs\brdrw10  Recovered\cell\row\pard\par\i SOC = System Organ Class\parNote: Adverse events were coded using MedDRA version XX.X.\i0\par\page{\*\bkmkstart list_16_2_8}\b Listing 16.2.8: Individual Laboratory Measurements\b0\par{\*\bkmkend list_16_2_8}\par\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600\b Study ID\cell Treatment\cell Patient ID\cell Visit\cell Date\cell Parameter\cell Result\cell Unit\cell Reference Range\cell Flag\b0\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Screening\cell 2023-01-02\cell Hemoglobin\cell 11.0\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Screening\cell 2023-01-26\cell WBC\cell 10.0\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Screening\cell 2023-01-15\cell Platelets\cell 342.9\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Screening\cell 2023-01-15\cell ALT\cell 12\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Screening\cell 2023-01-13\cell AST\cell 36\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Screening\cell 2023-01-03\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 2023-03-07\cell Hemoglobin\cell 11.6\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 2023-03-19\cell WBC\cell 10.8\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 2023-03-19\cell Platelets\cell 341.4\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 2023-03-19\cell ALT\cell 12\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 2023-03-12\cell AST\cell 35\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 4\cell 2023-03-21\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 2023-05-03\cell Hemoglobin\cell 12.9\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 2023-05-16\cell WBC\cell 9.4\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 2023-05-28\cell Platelets\cell 292.7\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 2023-05-05\cell ALT\cell 10\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 2023-05-19\cell AST\cell 35\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1001\cell Week 12\cell 2023-05-19\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Screening\cell 2023-01-19\cell Hemoglobin\cell 11.9\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Screening\cell 2023-01-15\cell WBC\cell 10.4\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Screening\cell 2023-01-14\cell Platelets\cell 326.7\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Screening\cell 2023-01-17\cell ALT\cell 12\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Screening\cell 2023-01-26\cell AST\cell 36\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Screening\cell 2023-01-28\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 2023-03-27\cell Hemoglobin\cell 11.4\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 2023-03-11\cell WBC\cell 9.8\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 2023-03-03\cell Platelets\cell 309.7\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 2023-03-14\cell ALT\cell 12\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 2023-03-22\cell AST\cell 37\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 4\cell 2023-03-08\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 2023-05-07\cell Hemoglobin\cell 12.4\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 2023-05-21\cell WBC\cell 10.1\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 2023-05-12\cell Platelets\cell 316.9\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 2023-05-16\cell ALT\cell 10\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 2023-05-07\cell AST\cell 36\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell B\cell SUBJ-1002\cell Week 12\cell 2023-05-27\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Screening\cell 2023-01-12\cell Hemoglobin\cell 12.7\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Screening\cell 2023-01-10\cell WBC\cell 9.1\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Screening\cell 2023-01-22\cell Platelets\cell 312.4\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Screening\cell 2023-01-07\cell ALT\cell 12\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Screening\cell 2023-01-11\cell AST\cell 37\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Screening\cell 2023-01-11\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 2023-03-26\cell Hemoglobin\cell 11.9\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 2023-03-02\cell WBC\cell 9.4\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 2023-03-12\cell Platelets\cell 318.4\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 2023-03-22\cell ALT\cell 13\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 2023-03-04\cell AST\cell 36\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 4\cell 2023-03-22\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 2023-05-24\cell Hemoglobin\cell 11.2\cell g/dL\cell 13.0-17.0\cell L\cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 2023-05-20\cell WBC\cell 9.2\cell 10^9/L\cell 4.5-11.0\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 2023-05-24\cell Platelets\cell 331.4\cell 10^9/L\cell 150-450\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 2023-05-18\cell ALT\cell 11\cell U/L\cell 7-56\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 2023-05-07\cell AST\cell 39\cell U/L\cell 5-40\cell \cell\row\trowd\trgaph108\trleft-108\cellx800\cellx1600\cellx2400\cellx3200\cellx4000\cellx4800\cellx5600\cellx6600\cellx7600\cellx8600 STUDY001\cell A\cell SUBJ-1003\cell Week 12\cell 2023-05-01\cell Creatinine\cell 0.6\cell mg/dL\cell 0.6-1.2\cell L\cell\row\pard\par\i WBC = white blood cells; ALT = alanine aminotransferase; AST = aspartate aminotransferase\parFlags: H = above reference range; L = below reference range\parNote: This listing provides individual laboratory test results for all patients.\i0\par\par}